Adaptimmune Therapeutics (ADAP) Q4 2024 earnings summary

Executive summary

• TECELRA launch is ahead of schedule, with 20 of 30 planned ATCs operational and strong early momentum in patient treatment and revenue generation; 10 patients apheresed in Q1 2025 and 3 in 2024.

• Q4 2024 saw $1.2 million in product revenue from two invoiced patients, with Q1 2025 expected to see a significant increase in both apheresed and invoiced patients.

• Manufacturing performance has been robust, with 100% of released products meeting specifications and turnaround times under 30 days, and no capacity constraints.

• Reimbursement success is high, with over 70% of commercial and Medicare lives covered and no denials to date.

• Lete-cel pivotal trial met its primary endpoint with a 42% overall response rate and 6 complete responses; BLA submission planned for late 2025, with anticipated approval and launch in 2026–2027.

Financial highlights

• Q4 2024 product revenue was $1.2 million from two patients.

• Consensus analyst forecast of $25 million in TECELRA sales for 2025 is considered achievable.

• Peak US sales for the sarcoma franchise (TECELRA and lete-cel) are projected at approximately $400 million.

• Total liquidity at end of 2024 was $152 million, down from $147 million at end of 2023.

Outlook and guidance

• Sales of TECELRA are expected to accelerate each quarter in 2025 as more ATCs come online and patient throughput increases.

• Targeting full network of ~30 ATCs for TECELRA by end of 2025.

• Lete-cel is expected to more than double the number of treatable patients and eventually comprise over 60% of franchise revenue.

• The company aims to achieve cash flow break-even in 2027, with two FDA-approved sarcoma products driving profitability, supported by $300 million in cost savings over four years.